Home > Publications database > Plasma Metabolome Signature Indicative of BRCA1 Germline Status Independent of Cancer Incidence. > print

001     168525
005     20240229133610.0
024 7 _ |a 10.3389/fonc.2021.627217
|2 doi
024 7 _ |a pmid:33898308
|2 pmid
024 7 _ |a pmc:PMC8058469
|2 pmc
024 7 _ |a altmetric:104738234
|2 altmetric
037 _ _ |a DKFZ-2021-00957
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Penkert, Judith
|b 0
245 _ _ |a Plasma Metabolome Signature Indicative of BRCA1 Germline Status Independent of Cancer Incidence.
260 _ _ |a Lausanne
|c 2021
|b Frontiers Media
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1686908554_5459
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a Division of Tumour Metabolism and Microenvironment, German Cancer Research Center (DKFZ), Heidelberg, Germany.
520 _ _ |a Individuals carrying a pathogenic germline variant in the breast cancer predisposition gene BRCA1 (gBRCA1+) are prone to developing breast cancer. Apart from its well-known role in DNA repair, BRCA1 has been shown to powerfully impact cellular metabolism. While, in general, metabolic reprogramming was named a hallmark of cancer, disrupted metabolism has also been suggested to drive cancer cell evolution and malignant transformation by critically altering microenvironmental tissue integrity. Systemic metabolic effects induced by germline variants in cancer predisposition genes have been demonstrated before. Whether or not systemic metabolic alterations exist in gBRCA1+ individuals independent of cancer incidence has not been investigated yet. We therefore profiled the plasma metabolome of 72 gBRCA1+ women and 72 age-matched female controls, none of whom (carriers and non-carriers) had a prior cancer diagnosis and all of whom were cancer-free during the follow-up period. We detected one single metabolite, pyruvate, and two metabolite ratios involving pyruvate, lactate, and a metabolite of yet unknown structure, significantly altered between the two cohorts. A machine learning signature of metabolite ratios was able to correctly distinguish between gBRCA1+ and controls in ~82%. The results of this study point to innate systemic metabolic differences in gBRCA1+ women independent of cancer incidence and raise the question as to whether or not constitutional alterations in energy metabolism may be involved in the etiology of BRCA1-associated breast cancer.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a BRCA1 germline mutation
|2 Other
650 _ 7 |a HIF1 alpha
|2 Other
650 _ 7 |a NAD+ balance
|2 Other
650 _ 7 |a aerobic glycolysis
|2 Other
650 _ 7 |a breast cancer
|2 Other
650 _ 7 |a energy metabolism
|2 Other
650 _ 7 |a lactate
|2 Other
650 _ 7 |a plasma metabolome
|2 Other
700 1 _ |a Märtens, Andre
|b 1
700 1 _ |a Seifert, Martin
|b 2
700 1 _ |a Auber, Bernd
|b 3
700 1 _ |a Derlin, Katja
|b 4
700 1 _ |a Hille-Betz, Ursula
|b 5
700 1 _ |a Hörmann, Philipp
|b 6
700 1 _ |a Klopp, Norman
|b 7
700 1 _ |a Prokein, Jana
|b 8
700 1 _ |a Schlicker, Lisa
|0 P:(DE-He78)e52c8f6ae826320eaf2fb173e162070d
|b 9
|u dkfz
700 1 _ |a Wacker, Frank
|b 10
700 1 _ |a Wallaschek, Hannah
|b 11
700 1 _ |a Schlegelberger, Brigitte
|b 12
700 1 _ |a Hiller, Karsten
|b 13
700 1 _ |a Ripperger, Tim
|b 14
700 1 _ |a Illig, Thomas
|b 15
773 _ _ |a 10.3389/fonc.2021.627217
|g Vol. 11, p. 627217
|0 PERI:(DE-600)2649216-7
|p 627217
|t Frontiers in oncology
|v 11
|y 2021
|x 2234-943X
909 C O |p VDB
|o oai:inrepo02.dkfz.de:168525
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)e52c8f6ae826320eaf2fb173e162070d
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-319H
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Addenda
|x 0
914 1 _ |y 2021
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT ONCOL : 2019
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-01-27
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-01-27
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-01-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-27
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2021-01-27
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-01-27
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-01-27
920 1 _ |0 I:(DE-He78)A410-20160331
|k A410
|l Metabolismus und Microenvironment
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A410-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21